HUGE Bathi resik saben saham sajrone 12 wulan pungkasan FSD Pharma

Trailing twelve-month earnings per share on the GURU.Markets chart shows a decline for FSD Pharma Inc. (HUGE) due to austerity measures and the liquidation of non-core assets. This results from a strategic focus on developing precision drugs for neurodegeneration and strong confidence among scientists in the company's methods for combating brain inflammation. The value of -0.26 determines the current status of the parameter, helping investors assess real profit without market noise.

HUGE Bathi saben saham sajroning taun lumaku FSD Pharma (04.07.2022 - 15.08.2024)

fsdpharma.com - rincian analitis lan metrik utama (HUGE)

- rega saham lan target rega konsensus:

Rega saham FSD Pharma Inc.|HUGE - Rata-rata rega prakiraan

- data kapitalisasi pasar:

Biji pasar FSD Pharma Inc.|HUGE - Nilai Perusahaan

- indikator nilai aset resik miturut neraca:

Aset Bersih saben Siji Saham FSD Pharma|HUGE - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku fsdpharma.com|HUGE - Aset Perusahaan

- data tingkat utang lan likuiditas finansial:

- data bathi lan kelipatan valuasi:

HUGE - Bathi sawise pajeg|Bathi sing dikarepake FSD Pharma Inc.|HUGE - Periode bali modal bisnis|Pangali Forward P/E FSD Pharma Inc.|HUGE - Rasio P/E diaturake wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan FSD Pharma Inc.|HUGE - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan FSD Pharma|HUGE - Bathi saben siji saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan fsdpharma.com|HUGE - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep FSD Pharma Inc.

- rincian pendapatan lan dodolan emiten:

HUGE - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan FSD Pharma|HUGE - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang prakiraan pendapatan FSD Pharma Inc.

Analisis dhasar perusahaan:FSD Pharma Inc. (HUGE)

For the biotech company FSD Pharma Inc. (HUGE), which focuses on developing treatments for depression and PTSD, operational efficiency is driven by clinical trial expenditures. This indicator is calculated as the ratio of annual net income to the number of non-diluted shares. The metric allows for an assessment of the real return per share by excluding the impact of issuance factors. It is critical for investors to track capital dynamics amid the optimization of the patent portfolio. Analyzing the rolling net income per share helps identify business consolidation phases in a timely manner.

Analisis perusahaan pesaing